Analyst firms · Morgan Stanley · BMRN
Morgan Stanley BMRN price target and rating history
BioMarin Pharmaceutical Inc. (BMRN) · Health Care
Morgan Stanley rates BioMarin Pharmaceutical Inc. (BMRN) Overweight with a $120 price target, as of its latest action on Apr 27, 2026. It has published 4 rating actions on BMRN since November 2021, including 1 upgrade and 0 downgrades. Across 9 firms with a BMRN price target in the last 12 months, the median target is $88. Morgan Stanley's $120 is 36% above that.
- Current rating
- Overweight
- Price target
- $120
- Median target, all firms
- $88
- Actions on BMRN
- 4
Morgan Stanley price target on BMRN
Every Morgan Stanley rating on BMRN
- Apr 27, 2026
- Jul 3, 2025
- Apr 25, 2022
- Nov 22, 2021
How other firms rate BMRN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $88 | Oct 15, 2026 |
| Raymond James | Strong Buy | $109 | Oct 12, 2026 |
| BMO Capital Markets | Outperform | $98 | Aug 19, 2026 |
| Citigroup | Buy | $75 | May 19, 2026 |
| Goldman Sachs | Neutral | $69 | May 11, 2026 |
| Morgan Stanley | Overweight | $120 | Apr 27, 2026 |
| Barclays | Overweight | $80 | Jan 28, 2026 |
| Canaccord Genuity | Buy | $98 | Jan 20, 2026 |
| Leerink Partners | Market Perform | $60 | Dec 3, 2025 |
Questions about Morgan Stanley and BMRN
- What is Morgan Stanley's price target for BMRN?
- Morgan Stanley's latest stated price target for BioMarin Pharmaceutical Inc. (BMRN) is $120, from its action on Apr 27, 2026.
- What is Morgan Stanley's rating on BMRN?
- Morgan Stanley rates BMRN Overweight, a bullish rating, as of Apr 27, 2026.
- When did Morgan Stanley last change its view on BMRN?
- On Apr 27, 2026, Morgan Stanley resumes coverage at Overweight, price target $120.
- How does Morgan Stanley's BMRN target compare with other analysts?
- Across 9 firms with a BMRN price target in the last 12 months, the median target is $88. Morgan Stanley's $120 is 36% above that.
More BMRN rating histories
All Morgan Stanley ratingsBMRN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.